1 Memorial Sloan-Kettering Cancer Center and Weill Cornell ...

5/18/2011 “Adoptive Therapy of Cancer with T cells Genetically Targeted to TumorAssociated Antigens through the Introduction of Chimeric Antigen Receptors(CARs): Trafficking, Persistence, and Perseverance”, American Society of Geneand Cell Therapy 14 th Annual Meeting, Seattle, WA6/1/2011 “Adoptive Therapy of Cancer using Genetically Targeted T cells: EnhancingCAR design, preclinical studies, translation to the clinical setting, and addressingthe tumor microenvironment", Preston Robert Tisch Brain Tumor Center Seminar,Duke University, Durham, NC10/19/2011 “Adoptive T-cell Therapy of Cancer from the Bench Top to the Bedside andBeyond”, 2 nd Annual Asian Cellular Therapy Organization, Miyazaki, Japan10/21/2011 “Genetically Modified T cells for Cancer Therapy: Building the Perfect T cell”,National Cancer Center, Tokyo, Japan12/21/2011 “Adoptive therapy of B cell malignancies with genetically targeted T cells: Fromthe bench top to the bedside and back again”, Dana-Farber Cancer Institute,Boston, MA2/24/2012 “Chimeric Antigen Receptors (CARs): Adoptive therapy of B cell malignanciesutilizing CD19 targeted CAR modified T cells” Keynote Lecture, 16 th AnnualInternational Congress on Hematologic Malignancies, Snowbird, UT3/18/2012 “Adoptive Cell Therapy: Utilizing the Immune System to combat Cancer” &“Genetically Targeted T cells in Cancer Immunotherapy: the past, the present, andthe future”, Innovations in Oncology – Targeted Therapies and Cancer Program,Delhi, India4/13/2012 “Adoptive Therapy of Cancer of Cancer using Tumor Targeted T-cells: A GeneticApproach, Medical Grand Rounds at Roswell Park Cancer Institute, Buffalo, NY6/2/2012 Discussant, Poster Discussion Session – Developmental Therapeutics-ClinicalPharmacology and Immunotherapy Track, American Society of ClinicalOncology 48 th Annual Meeting, Chicago, IL6/6/2012 “Clinical Translation of an Adoptive Therapeutic Approach to Cancer: Obstaclesfrom the Perspective of an Academic Investigator”, International Society of CellTherapy 18 th Annual Meeting, Seattle, WA6/8/2012 “Chimeric Antigen Receptor (CAR) modified T cells as a novel approach toimmuno-therapy of B cell malignancies”, International Society of Cell Therapy18 th Annual Meeting, Seattle, WA9/9/2012 “CAR modified T cell therapy: Future directions and moving beyond the singlecenter setting”, 10 th International Workshop on Non-Hodgkin Lymphoma,Boston, MA12